Advertisement

Topics

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

2016-08-29 14:10:19 | BioPortfolio

Published on BioPortfolio: 2016-08-29T14:10:19-0400

Clinical Trials [2491 Associated Clinical Trials listed on BioPortfolio]

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indicat...

Barostim Therapy for Heart Failure

The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.

BAROSTIM THERAPY™ In Resistant Hypertension

The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indicat...

Evaluation of Baroreflex Activation Therapy in Patients With Advanced Heart Failure

The objective of this single center prospective clinical trial is to evaluate the safety and efficacy of carotid Baroreflex Activation Therapy (BAT) in advanced heart failure (HFrEF). Beyo...

Feasibility Study of an Integrated Diagnostic System to Manage Heart Failure

The purpose of this clinical trial is to evaluate the potential benefits of a new heart failure diagnostic system for heart failure patients with implanted cardiac resynchronization therap...

PubMed Articles [14430 Associated PubMed Articles listed on BioPortfolio]

Common Postoperative Heart Transplant Complications.

Heart failure or congestive heart failure remains a major public health concern on the global scale. End-stage heart failure is a severe disease where the heart is unable to pump enough oxygen and nut...

In-hospital and 3-year outcomes of heart failure patients in South India: The Trivandrum Heart Failure Registry.

Long-term data on outcomes of participants hospitalized with heart failure (HF) from low and middle-income countries are limited.

Prospective evaluation of integrated device diagnostics for heart failure management: results of the TRIAGE-HF study.

The primary aim of the TRIAGE-HF trial was to correlate cardiac implantable electronic device-generated heart failure risk status (HFRS) with signs, symptoms, and patient behaviours classically associ...

Coordinated heart failure care in Poland: towards optimal organisation of the health care system.

Heart failure has becoming an increasing medical, economic, and social problem globally. The prevalence of this syndrome is rising, and despite unequivocal positive effects of modern therapy, reductio...

Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction.

Medical and Biotech [MESH] Definitions

A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Heart failure caused by abnormal myocardial relaxation during DIASTOLE leading to defective cardiac filling.

Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.

A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

More From BioPortfolio on "BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial